CEACAM5 and cancer: Therefore, in search for more reliable markers other than CEA and CA19-9, many researchers have focused on aberrant N-glycoproteins in cancer, and have evaluated their clinical usefulness as markers; the representative of which is alphafetoprotein-L3 (AFP-L3), as a marker for hepatocellular carcinoma.